004310 — Hyundai Pharmaceutical Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeSmall CapSucker Stock

Annual income statement for Hyundai Pharmaceutical Co, fiscal year end - November 30th, KRW millions except per share, conversion factor applied.

	2021 November 30th	2022 November 30th	2023 November 30th	2024 November 30th	2025 November 30th
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	139,803	162,690	180,763	175,735	191,790
Cost of Revenue
Gross Profit	56,313	68,837	76,593	73,366	79,605
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	143,872	154,735	186,584	175,569	187,629
Operating Profit	-4,069	7,955	-5,821	166	4,161
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-4,021	5,670	8,034	-1,733	2,307
Provision for Income Taxes
Net Income After Taxes	-3,173	-165	6,122	-575	2,516
Net Income Before Extraordinary Items
Net Income	-3,173	-165	6,122	-575	2,516
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	-3,173	-165	6,122	-575	2,516
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-55.6	-5.71	558	-21.8	96.2
Dividends per Share